the sun malaysia ipaper logo 150x150
Friday, July 3, 2026
27.5 C
Kuala Lumpur
the sun malaysia ipaper logo 150x150

Covid-19: 15% Sarawakian parents disagree on child vaccination

KUCHING: As many as 15 per cent of the 40,000 respondents among parents in Sarawak disagreed with having their children vaccinated under the Covid-19 Immunisation Programme for Children (PICKids), said Deputy Chief Minister Datuk Amar Douglas Uggah Embas.

He said the results of the Sarawak Health Department survey from Jan 26 to 31 also found that 59.7 per cent agreed to it while 25.3 per cent were unsure.

He said one of the main reasons respondents disagreed or were unsure was because of concerns about the complications that would occur after taking the vaccine.

“Some are worried about the safety of the vaccine and want to be given the advantage of choosing the type of vaccine,” said Uggah who is also State Disaster Management Committee (JPBN) chairman to reporters after the launch of the state-level PICKids at the Sarawak General Hospital here today.

Yesterday, Health Minister Khairy Jamaluddin was quoted as saying that a total of 517,107 children, aged five to 11, in the country had been registered by their parents to receive the Pfizer COVID-19 vaccine as of Feb 1.

He said the figure covered about 15 per cent of the total cohort of 3.6 million children.

Meanwhile, Uggah said a total of 272,500 children aged five to 11 in Sarawak were eligible for PICKids.

“We are targeting 70 per cent of eligible children and in the education system to be given the first dose of Pfizer vaccine within two months from now,” he said. — Bernama

STAY AHEAD OF THE CURVE

Join our community for instant updates and exclusive content.

Join Telegram Channel

Related


spot_img

Latest News

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations

TAIPEI, TAIWAN - Media OutReach Newswire - 2 July 2026 - Bora Pharmaceuticals Co., Ltd. ("Bora" or "Bora Group"; TWSE: 6472; OTCQX: BORAY) today announced the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. (NASDAQ: MGNX) including its biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for total consideration of US $122.5 million through its wholly owned subsidiary Bora Biologics USA, LLC.. Upon closing, Bora signed a long-term CDMO Service Agreement with MacroGenics.

Most Viewed

spot_img
WC26

World Cup 2026

Updates, Fixtures, Results & Standings